Using microarray analysis, transgenic mice/cells, and tumor models, we identify acGM-1.8 as a new, specific, and safe TLR-2 agonist with the potential to regulate both innate and adaptive anti-cancer immune responses in vivo. This evidence concerns the gene TLR2 and cancer.